Ferring Pharmaceuticals today announced that Aaron Graff has been appointed Chief Executive Officer of Ferring Holding Inc.
In this role Mr. Graff assumes direct responsibility for all Ferring US activities including commercial operations (Ferring Pharmaceuticals Inc.), clinical development (Ferring International PharmaScience Center US), and manufacturing (Ferring Production Inc.).
“A US-based CEO helps ensure that important decisions concerning the US business benefit from the insight that only close proximity to the market provides,” comments Mr. Graff.
As CEO, Mr. Graff reports to the board of directors of Ferring Holding Company Inc., chaired by Michel Pettigrew, President of the Executive Board and Chief Operating Officer, Ferring Group.
Since joining Ferring Pharmaceuticals Inc. as President and Chief Operating Officer in 2010, Mr. Graff has overseen consistent double-digit annual growth in the US subsidiary and the expansion of its US presence to include an integrated operations center. This center, located in Parsippany, New Jersey, includes product development, manufacturing, commercial and all necessary medical, regulatory, and support functions.
Originally from Niagara Falls, New York, Mr. Graff joined Ferring in 2002 as Vice President, Global Marketing and Business Development based in Denmark. He later became Senior Vice President, Asia Region and Global Marketing based at the company’s global headquarters in Switzerland.
Prior to joining Ferring, Mr. Graff worked for over 17 years at Bristol-Myers Squibb in both the USA and Europe. His responsibilities included a broad variety of commercial positions in prescription pharmaceuticals and non-prescription medicines.
Source: Ferring Pharmaceuticals Inc.
As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.
McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.
AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.